Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.254
Peer-review started: March 11, 2021
First decision: May 11, 2021
Revised: May 20, 2021
Accepted: July 12, 2021
Article in press: July 12, 2021
Published online: January 7, 2022
Processing time: 294 Days and 4.9 Hours
There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB). More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.
We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high TMB. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo.
This is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.
Core Tip: Eighty percent of patients with positive programmed death-ligand 1 (PD-L1) expression are unable to benefit from immunotherapy. Herein, we report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high tumor mutational burden. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo. More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.